Data as of Jul 21
| +0.069 / +1.82%|
Amicus Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for the treatment of rare diseases, pharmacological chaperones are a novel, first-in-class approach to treating a broad range of diseases, including lysosomal storage disorders and diseases of neurodegeneration. Amicus develops pharmacological chaperones oral therapies that bind to and stabilize the affected proteins, restoring their shape, proper trafficking, and biological activity. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ.
|John F. Crowley||Chairman, President & Chief Executive Officer|
|Bradley L. Campbell||Chief Operating Officer|
|William D. Baird||Chief Financial Officer|
|Enrique Dilone||Vice President-Technical Operations|
|Robert E. Winkler||Vice President-Clinical Research & Operations|